Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Patient with multiple metastases, not eligible for surgery, might not profit from intensive
chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease
control may be a better choice for first line treatment. Therefore this study investigates
the combination of capecitabine and bevacizumab versus the combination of capecitabine,
bevacizumab and irinotecan. In case of progressive disease, the therapy in patients treated
with capecitabine and bevacizumab is intensified by adding irinotecan. Primary endpoint is
time-of-failure strategy (TFS) comparing both treatment arms.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003666
  •   2012/05/03
  •   2010/11/29
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2009-013099-38 
  •   NCT01249638  (
  •   ML22011  (Ludwig-Maximilians - University of Munich)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Colorectal Cancer Metastatic
  •   C20 -  Malignant neoplasm of rectum
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Capecitabine
  •   Drug: Bevacizumab
  •   Drug: Capecitabine
  •   Drug: Irinotecan
  •   Drug: Bevacizumab
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- TFS; time frame: 9 months; Time of Failure Strategy

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- ORR, OS, Quality of Life, PFS-1; time frame: 36 months

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2010/12/31
  •   516
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Histologically confirmed adenocarcinoma of the colon or rectum.

- Stage IV disease.

- ECOG 0-1.

- Patients considered suitable for application of chemotherapy.

- Age 18 - 75 years.

- In- or outpatient treatment.

- Estimated life expectancy > 3 months.

- Measurable index lesion according to RECIST criteria. Evaluation of tumor
manifestations ≤ 2 weeks prior to treatment start.

- Effective contraception.

- Adequate hematologic function: leukocytes >= 3000/µl, neutrophils >= 1500/µl,
platelets >= 100.000/µ, and hemoglobin >= 9g/dl. Bilirubin <= 1,5x upper limit of
normal (ULN). ALAT and ASAT <= 2,5x ULN, in case of liver metastases <= 5x ULN. Serum
creatinine <= 1,5x ULN.

- No operations within 4 weeks prior to treatment start. No cytologic biopsies within 1
week prior to treatment start. Operation sequels need to be completely healed. Major
operations must not be expected at time of study begin, except for potential
secondary resection of liver metastases. In case of secondary resection of liver
metastases, bevacizumab must be discontinued 6-8 weeks prior to surgery.

- No relevant toxicities due to prior medical treatment at time of study entry.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- primary resectable metastases

- heart failure Grade III/IV (NYHA-classification)

- Prior treatment directed against the epidermal growth factor receptor (EGFR).

- Prior treatment with bevacizumab.

- Prior chemotherapy for colorectal cancer, except for adjuvant chemotherapy dating
back > 6 months prior to study entry.

- Experimental medical treatment within 30 days prior to study entry.

- Known hypersensitivity reaction to any study medication.

- Pregnant or breast feeding women (pregnancy needs to be excluded by testing of

- Known or suspected cerebral metastases.

- Clinically significant coronary heart disease, myocardial infarction within the last
12 months or high risk of uncontrolled arrhythmia.

- Acute or subacute ileus, chronic inflammatory bowel disease or chronic diarrhea.

- Abdominal or tracheo-esophageal fistulas, gastrointestinal perforation within 6
months before study entry

- Symptomatic peritoneal carcinosis.

- Severe chronic wounds, ulcera or bone fracture.

- Uncontrolled hypertension.

- Severe proteinuria (nephrotic syndrome).

- Arterial thromboembolic events or hemorrhage within 6 months prior to study entry
(except tumor bleeding surgically treated by tumor resection).

- Bleeding diatheses or coagulopathy.

- Full dose anticoagulation.

- Known DPD-deficiency (special screening not required).

- Known glucuronidation-deficiency (special screening not required).

- Contraindication with irinotecan

- Medical history of other malignant disease within 5 years prior to study entry,
except for basalioma, and in-situ cervical carcinoma if treated with curative intent.

- Known alcohol or drug abuse.

- Medical or psychiatric condition which contradicts participation of study.

- Limited legal capacity.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Ludwig-Maximilians - University of Munich
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • University of Munich - Klinikum der Universitaet Muenchen
    • Volker Heinemann, Prof. Dr. med. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Volker Heinemann, Prof. Dr. 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   92
  •   2013/10/30
* This entry means the parameter is not applicable or has not been set.